Professor Norman J Maitland
Director YCR Cancer Research Unit



1991 - Professor of Molecular Biology, Director YCR Cancer Research Unit Department of Biology, University of York
1989 - 1991 Senior Lecturer in Molecular Pathology  Department of Pathology, University of Bristol
1983 - 1989 New Blood Lecturer in Molecular Pathology Department of Pathology, University of Bristol 
1977 - 1983 Cancer Research Campaign Research Fellow Department of Genetics, University of Edinburgh
1976 - 1977 Robertson Research Fellow Cold Spring Harbor Laboratory, New York
1974 - 1977 PhD in Cancer Studies University of Birmingham
1970 - 1974 BSc Biochemistry (First Class Hons) University of Glasgow           



My research in the YCR Cancer Research Unit is now focused on the development and aetiology of human prostate cancer. Our overall approach has been to separate the tumour (and the corresponding normal tissue) into its cellular components, and to study the role played by different cell types. Of particular interest are the roles played by epithelial stem cells and the hormone-sensitive stromal cells within the tumour and normal prostate. We have compiled gene expression profiles for the various cell types using the Affymetrix platform, and have mined this data for genes and signalling pathways which affect cell fate. Much of our research is now concerned with hypothesis testing, based on the identified genes from this study, using complex multicellular models in vitro and developing xenograft models of the tumour. Clearly fate-altering genes also have therapeutic significance, and in a spin out company (Pro-Cure Therapeutics, founded in 2001) an associated research team are developing novel cancer stem cell treatments, based on the output of the YCR Research. There is a close collaboration between the two groups. As part of an International collaboration, coordinated from York, we are also developing novel biotherapies for prostate cancer, based on targeted and stealthed viral vectors, which allow us to either focus gene expression in specific cells within a tumour, or to engineer viruses to replicate only in tumour cells (oncolytics).


We have shown that heterogeneity within human prostate cancers is due to both carcinogenic changes but also aberrant differentiation, which are two independent events. Current therapies are directed against the majority of cells in the tumour (the most differentiated cells) but do not affect the minority population, which are the tumour initiating cells or cancer stem cells. Thus these cells form a root for post therapy recurrence. By exploiting our gene expression profiling of these cells we have designed potentially novel treatments, which could delay or even prevent tumour recurrence. However we have also shown that the cancer stem cells have an active resistance mechanism to many therapies, such as radiotherapy and chemotherapy. By exploiting a novel ex vivo human blood loop system we have shown that a powerful complement response can eliminate the therapeutic doses of gene therapy vectors, and that co-inoculation with 2 complement inhibitors can block this effect (not seen in mouse models).


  • In Vitro Models of Human Prostate Carcinoma including Isolation Characterisation of Stem Cells (Funding body: Yorkshire Cancer Research)
  • The Molecular Basis of Metastasis in Human Prostate Cancer (Funding body: NCRI/Yorkshire Cancer Research)
  • DNA Damage Response in Prostate Cancer Stem Cells (Funding body: Yorkshire Cancer Research)
  • Prostate Research Organisations - Network of Early Stage Training (ProNest), Marie Curie (Funding Body: European Union)
  • Mapping the Epigenetic Lanscape in Prostate Cancer Stem Cells (Funding Body: The Freemasons Grand Charity/Yorkshire Cancer Research)
  • Targeting the PTEN/AKT/m/TOR pathway in human prostate cancer (Funding Body: BBSRC Industrial CASE Studentship with Astra Zeneca)

Research group(s)

Research Staff

Professor Norman J Maitland - Director of the YCR Cancer Research Unit and YCR Professor of Molecular Biology Ext: 8700

Dr Anne Collins is a Senior Research Associate studying the role of stem cells in prostate cancer. Ext: 8707

Dr Marie Labarthe-Last is a Postdoctoral Researcher investigating the role of the tumour-initiating population in therapy resistance in prostate cancer. Ext:8707

Dr Fiona Frame is a Postdoctoral Researcher studying the irradiation-induced DNA damage response in prostate cancer stem cells. Ext: 8708

Support Staff

Michelle Scaife is secretary to Professor Maitland and also looks after the administrative needs of the Unit. Ext: 8711 (Works: Monday, Wednesday and Friday)

Hannah Walker is a full-time Senior Research Technician. Ext: 8721

Li Xiang is a part time Laboratory Assistant Ext: 8721


Alberto Taurozzi is a graduate student studying the deregulation of stem cell maintenance mechanisms that occurs in prostate cancer. Ext: 8701

Adam Hirst is a joint graduate student with the York Plasma Institute studying the effects of low termperature plasmas on prostate cancer. Ext: 8701

John Packer is a graduate student investigating monoallelic expression of genes that are critical in prostate cancer initiation and development. Ext: 8701

Leanne Archer is a graduate student investigating the role of the ELF3 transcription factor in prostate cancer. Ext: 8701


Contact details

Prof. Norman J Maitland
Director YCR Cancer Research Unit
Department of Biology (Area 13)
University of York
YO10 5DD

Tel: 01904 328700